share_log

HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $11 Price Target

HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $11 Price Target

HC Wainwright & Co.重申对Y-mabs Therapeutics的买入,维持11美元的目标股价
Benzinga ·  2023/11/15 07:21

HC Wainwright & Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and maintains $11 price target.

HC Wainwright & Co. 分析师罗伯特·伯恩斯重申了Y-mabs Therapeutics(纳斯达克股票代码:YMAB)的买入,并维持11美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发